Management of fabry disease with agalsidase treatment

Clinical Medicine Insights: Therapeutics

Volumn 2, Issue , 2010, Pages 953-963

  Pintos Morell, Guillem ^a   Lidove, Olivier ^b   Mehta, Atul ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Agalsidase alfa; Agalsidase beta; Enzyme replacement therapy; Fabry disease; Lysosomal storage disorder

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; PLACEBO;

CARDIOMYOPATHY; CHILL; CREATININE CLEARANCE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME REPLACEMENT; FABRY DISEASE; FLUSHING; GLOMERULUS FILTRATION RATE; HUMAN; INJECTION SITE REACTION; KIDNEY FUNCTION; NAUSEA; NEUROPATHIC PAIN; PEDIATRICS; QUALITY OF LIFE; REVIEW; RIGOR; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 78650729342     PISSN: 1179559X     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/CMT.S6104     Document Type: Review

References (95)

1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase defciency. N Engl J Med. 1967;276:1163-1167.
2. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249-254.
3. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31-40.
4. Mehta A, Eykens F, Feliciani C, et al. Fabry disease: A review of current management strategies. QJM. 2010;103:641-659.
5. Mehta A. Agalsidase alfa for enzyme replacement therapy in Fabry disease. Expert Rev. Endocrinol Metab. 2010;5(5):641-652.
6. Lidove O, West M, Pintos-Morell G, et al. Effects of enzyme replacement therapy in Fabry disease-a comprehensive review of the medical literature. Genet Med. 2010. (In press, due for publication 2010 Nov 15 and Pub Med ahead of print, 2010 Oct 25).
7. Mehta A, West M, Pintos-Morell G, et al. Therapeutic goals in the treatment of Fabry disease, Genet Med. 2010. (In press, due for publication 2010 Nov 15 and Pub Med ahead of print, 2010 Oct 25).
8. Ramaswami U, Whybra C, Parini R, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 2006;95:86-92.
9. Pintos-Morell G, Beck M. Fabry disease in children and the effects of enzyme replacement treatment. Eur J Pediatr. 2009;168:1355-1363.
10. Marchesoni CL, Roa N, Pardal AM, et al. Misdiagnosis in Fabry disease. J Pediatr. 2010;156(5):828-831.
11. Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. Arch Ophthalmol. 1979;97:671-676.
12. Thadhani R, Wolf M, West ML, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int. 2002;61:249-255.
13. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009; 24:2102-2111.
14. Mehta A, Clarke JT, Giugliani R, et al. Natural course of Fabry disease: changing pattern of causes of death in FOS-Fabry Outcome Survey. J Med Genet. 2009;46:548-552.
15. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: fndings from the Fabry Registry. Genet Med. 2009;11:790-796.
16. Warnock DG, West ML. Diagnosis and management of kidney involvement in Fabry disease. Adv Chronic Kidney Dis. 2006;13:138-147.
17. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750-760.
18. Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol. 2008; 130:367-373.
19. Schiffmann R, Ries M. Fabry's disease-an important risk factor for stroke. Lancet. 2005;366:1754-1756.
20. Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events. Natural history data from the Fabry registry. Stroke. 2009;40:788-794.
21. Hopkin RJ, Bissler J, Banikazemi M, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res. 2008; 64:550-555.
22. Ries M, Gupta S, Moore DF, et al. Pediatric Fabry disease. Pediatrics. 2005; 115:344-355.
23. Kampmann C, Wiethoff CM, Whybra C, Bachner FA, Mengel E, Beck M. Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr. 2008;97:463-469.
24. Ries M, Clarke JT, Whybra C, et al. Enzyme-replacement therapy with agal-sidase alfa in children with Fabry disease. Pediatrics. 2006;118:924-932.
25. Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD. Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention. Qual Life Res. 2002;11:127-133.
26. Gold KF, Pastores GM, Botteman MF, et al. Quality of life of patients with Fabry disease. Qual Life Res. 2002;11:317-327.
27. Whybra C, Kampmann C, Willers I, et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis. 2001;24:715-724.
28. Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a signifcant burden of disease and impaired quality of life. Genet Med. 2007;9:34-45.
29. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38:769-775.
30. Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93:112-128.
31. Maier EM, Osterrieder S, Whybra C, et al. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr. 2006;95(Suppl):30-38.
32. Whybra C, Kampmann C, Krummenauer F, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004;65:299-307.
33. Vedder AC, Strijland A, vd Bergh Weerman MA, Florquin S, Aerts JM, Hollak CE. Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis. 2006;29:106-111.
34. Young E, Mills K, Morris P, Vellodi A, Lee P, Waldek S, et al. Is globotri-aosylceramide a useful marker in Fabry disease? Acta Paediatr. 2005;94 (Suppl):51-54.
35. Bekri S, Lidove O, Jaussaud R, Knebelmann B, Barbey F. The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the effcacy of treatment of Fabry disease: a review of the literature. Cardiovasc Hematol Agents Med Chem. 2006;4:289-297.
36. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008;105:2812-2817.
37. Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, et al. Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease. Biochem Biophys Acta. 2010;1802:741-748.
38. Sakuraba H, Murata-Ohsawa M, Kawashima I, et al. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fbro-blasts and Fabry mice. J Hum Genet. 2006;51:180-188.
39. Lee K, Jin X, Zhang K, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology. 2003;13:305-313.
40. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743-2749.
41. Schiffmann R, Martin RA, Reimschisel T, et al. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr. 2010;156:832-837.
42. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 2006;21: 345-354.
43. Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa. Heart. 2008;94:153-158.
44. West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol. 2009;20:1132-1139.
45. Eng CM, Guffon N, Wilcox WR, et al. Safety and effcacy of recombinant human a-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med. 2001;345:9-16.
46. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18:1547-1557.
47. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146:77-86.
48. Kampmann C, Linhart A, Devereux RB, Schiffmann R. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyo-pathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis. Clin Ther. 2009;31:1966-1976.
49. Whybra C, Miebach E, Mengel E, et al. A 4-year study of the effcacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med. 2009;11:441-449.
50. Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 2003;28:703-710.
51. Schiffmann R, Hauer P, Freeman B, et al. Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve. 2006; 34:53-56.
52. Moore DF, Scott LT, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation. 2001;104:1506-1512.
53. Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol. 2002;2:4.
54. Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood fow velocities in Fabry disease with reversal after enzyme replacement. Stroke. 2002;33:525-531.
55. Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and effcacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004; 75:65-74.
56. Jardim L, Vedolin L, Schwartz IV, et al. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis. 2004;27:229-240.
57. Jardim LB, Aesse F, Vedolin LM, et al. White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up. Arq Neuropsiquiatr. 2006;64:711-717.
58. Buechner S, Moretti M, Burlina AP, Cei G, Manara R, Ricci R, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry. 2008;79: 1249-1254.
59. Hajioff D, Enever Y, Quiney R, Zuckerman J, Mackermot K, Mehta A. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis. 2003;26:787-794.
60. Palla A, Hegemann S, Widmer U, Straumann D. Vestibular and auditory defcits in Fabry disease and their response to enzyme replacement therapy. J Neurol. 2007;254:1433-1442.
61. Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis. 2003;26:617-627.
62. Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30:184-192.
63. Mehta A, Ricci R, Widmer U, et al. Fabry disease defned: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34:236-242.
64. Dehout F, Roland D, Treille de Granseigne S, Guillaume B, van Maldergem L. Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease. J Inherit Metab Dis. 2004;27:499-505.
65. Parini R, Rigoldi M, Santus F, et al. Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson-Fabry disease: testing the effects with the Mainz Severity Score Index. Clin Genet. 2008; 74:260-266.
66. Mehta A, Beck M, Elliott P, et al; Fabry Outcome Survey investigators. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet. 2009;374:1986-1996.
67. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical beneft of enzyme replacement therapy in Fabry disease. Kidney Int. 2006; 69:1216-1221.
68. Elliott PM, Kindler H, Shah JS, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with a galactosidase A. Heart. 2006;92:357-360.
69. Kalliokoski RJ, Kantola I, Kalliokoski KK, et al. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis. 2006;29:112-118.
70. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation. 2003;108:1299-1301.
71. Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci M V, Procaccini D, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet. 2004;66:158-165.
72. Beer M, Weidemann F, Breunig F, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol. 2006;97:1515-1518.
73. Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009;119:524-529.
74. Imbriaco M, Pisani A, Spinelli L, et al. Effects of enzyme replacement therapy in patients with Anderson-Fabry disease: a prospective long term cardiac magnetic resonance imaging study. Heart. 2009;95:1103-1107.
75. Hilz MJ, Brys M, Marthol H, Stemper B, Dutsch M. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fbers in Fabry neuropathy. Neurology. 2004;62:1066-1072.
76. Ramaswami U, Wendt S, Pintos-Morell G, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr. 2007;96:122-127.
77. Wraith JE, Tylki-Szymanska A, Guffon N, et al. Safety and effcacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr. 2008;152:563-570.
78. Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE. 2007;2:e598.
79. Mehta A, Beck M, Kampmann C, Frustaci A, Germain DP, Pastores GM, et al. Enzyme replacement therapy in Fabry disease: comparison of agalsi-dase alfa and agalsidase beta. Mol Genet Metab. 2008;95:114-115.
80. Clarke JT, West ML, Bultas J, Schiffmann R. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. Genet Med. 2007;9:504-509.
81. Schiffmann R, Askari H, Timmons M, et al. Weekly enzyme replacement may show decline of renal function in patients with Fabry disease who are on long term biweekly dosing. J Am Soc Nephrol. 2007;18:1576-1583.
82. Lubanda JC, Anijala E, Bzduch V, et al. Evaluation of a low dose after a standard therapeutic dose of agasidase beta during enzyme replacement therapy in patient with Fabry disease. Genet Med. 209;11:256-264.
83. ®-summary of product characteristics. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/replagal/replagal.htm
84. ®-summary of product characteristics. Available at http://www.emea.europa.eu/humandocs/Humans/EPAR/fabrazyme/fabrazyme.htm
85. Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab. 2008;94:319-325.
86. Hollack CE, Linthorst GE. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome? Mol Genet Metab. 2009; 96:1-3.
87. Linthorst GE, Hollak C, Donker-Koopman WE, Strijland A, Aerts JMFG. Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004;66:1589-1595.
88. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/07/WC500094245.pdf
89. Cousins A, Lee P, Rorman D, et al. Home-based infusion therapy for patients with Fabry disease. Br J Nurs. 2008;17:653-657.
90. Milligan A, Hughes D, Goodwin S, Richfeld L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs. 2006; 15:330-333.
91. Hughes DA, Mlilligan A, Mehta A. Home therapy for lysosomal storage disorders. Br J Nurs. 2007;16:1384-1389.
92. Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol. 2007; 18:2609-2617.
93. Fan JQ. A counterintuitive approach to treat enzyme defciencies: use of enzyme inhibitors for restoring mutant enzyme activity. Biol Chem. 2008; 389:1-11.
94. Schiffmann R, Germain DP, Castelli J, Shenker A, Lockhart DJ. Phase 2 clinical trials of the pharmacological chaperone AT1001 for the treatment of Fabry disease. Proceedings of the 58th Annual Meeting of the American Society of Human Genetics (ASFG). Philadelphia, PA, USA 2008.
95. Heare T, Alp NJ, Priestman DA, et al. Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N- butyldeoxynojirimycin treatment. J Inherit Metab Dis. 2007;30:79-87.